

# *UnitedHealthcare Commercial* **Medical Policy Update Bulletin: October 2021**

Access a policy listed below for complete details on the latest updates. A comprehensive summary of changes is provided at the bottom of every policy document for your reference. To view a detailed version of this bulletin, click here.

# **Take Note**

## Annual ICD-10 Diagnosis Code and Quarterly CPT® and HCPCS Code Updates

Effective Oct. 1, 2021, all applicable Medical Policies, Medical Benefit Drug Policies, Coverage Determination Guidelines, and Utilization Review Guidelines have been updated to reflect the annual ICD-10 diagnosis code and quarterly CPT/HCPCS code additions, revisions, and deletions. Refer to the following sources for information on the code updates:

- American Medical Association. Current Procedural Terminology: CPT<sup>®</sup>
- Centers for Medicare & Medicaid Services (CMS) International Classification of Diseases, Tenth Revision (ICD-10) Clinical Modification (CM) (Diagnosis) Codes
- Centers for Medicare & Medicaid Services (CMS) International Classification of Diseases, Tenth Revision (ICD-10)
  Procedure Coding System (PCS) Codes
- Centers for Medicare & Medicaid Services. Healthcare Common Procedure Coding System: HCPCS Level II

For the list of impacted policies and corresponding details, click here.

# **Medical Policy Updates**

| Policy Title   | Status  | Effective Date |
|--|---------|----------------|
| Ablative Treatment for Spine Pain  | Updated | Nov. 1, 2021   |
| Computer-Assisted Surgical Navigation for Musculoskeletal Procedures                   | Updated | Oct. 1, 2021   |
| Deep Brain and Cortical Stimulation  | Revised | Nov. 1, 2021   |
| Electric Tumor Treatment Field Therapy   | Revised | Nov. 1, 2021   |
| Electrical Stimulation for the Treatment of Pain and Muscle Rehabilitation             | Updated | Nov. 1, 2021   |
| Epidural Steroid Injections for Spinal Pain  | Updated | Nov. 1, 2021   |
| Facet Joint Injections for Spinal Pain   | Updated | Nov. 1, 2021   |
| Gender Dysphoria Treatment   | Updated | Oct. 1, 2021   |
| Gender Dysphoria Treatment   | Updated | Nov. 1, 2021   |
| Genetic Testing for Neuromuscular Disorders  | Revised | Oct. 1, 2021   |
| Glaucoma Surgical Treatments   | Updated | Nov. 1, 2021   |
| Hysterectomy   | Updated | Nov. 1, 2021   |
| Implanted Electrical Stimulator for Spinal Cord  | Updated | Nov. 1, 2021   |
| Implanted Spinal Drug Delivery Systems   | Updated | Nov. 1, 2021   |
| Intrauterine Fetal Surgery   | Revised | Nov. 1, 2021   |
| Liposuction for Lipedema   | Updated | Nov. 1, 2021   |
| Minimally Invasive Procedures for Gastroesophageal Reflux Disease (GERD) and Achalasia | Revised | Nov. 1, 2021   |
| Obstructive and Central Sleep Apnea Treatment  | Updated | Nov. 1, 2021   |

| Policy Title   | Status  | Effective Date |
|--|---------|----------------|
| Prostate Surgeries and Interventions   | Updated | Nov. 1, 2021   |
| Sacroiliac Joint Interventions   | Updated | Nov. 1, 2021   |
| Spinal Fusion Enhancement Products   | Revised | Nov. 1, 2021   |
| Surgery of the Elbow   | Updated | Nov. 1, 2021   |
| Surgical and Ablative Procedures for Venous Insufficiency and Varicose Veins | Updated | Nov. 1, 2021   |
| Surgical Treatment for Spine Pain  | Updated | Nov. 1, 2021   |
| Temporomandibular Joint Disorders  | Updated | Nov. 1, 2021   |
| Total Artificial Heart and Ventricular Assist Devices                        | Updated | Nov. 1, 2021   |
| Vagus and External Trigeminal Nerve Stimulation                              | Updated | Nov. 1, 2021   |

# **Medical Benefit Drug Policy Updates**

| Policy Title   | Status  | Effective Date |
|--|---------|----------------|
| Antiemetics for Oncology                                 | Revised | Nov. 1, 2021   |
| Cimzia® (Certolizumab Pegol)                             | Updated | Oct. 1, 2021   |
| Medical Therapies for Enzyme Deficiencies                | Revised | Oct. 1, 2021   |
| Oncology Medication Clinical Coverage                    | Revised | Nov. 1, 2021   |
| Respiratory Interleukins (Cinqair®, Fasenra®, & Nucala®) | Revised | Nov. 1, 2021   |
| Ryplazim® (Plasminogen, Human-Tvmh)                      | New     | Oct. 1, 2021   |
| Saphnelo™ (Anifrolumab-Fnia)                             | New     | Oct. 1, 2021   |
| Sodium Hyaluronate                                       | Revised | Nov. 1, 2021   |
| Synagis® (Palivizumab)                                   | Revised | Nov. 1, 2021   |

# **Coverage Determination Guideline Updates**

| Policy Title  | Status  | Effective Date |
|---|---------|----------------|
| Beds and Mattresses                                       | Revised | Nov. 1, 2021   |
| Breast Reconstruction Post Mastectomy and Poland Syndrome | Updated | Nov. 1, 2021   |
| Cosmetic and Reconstructive Procedures                    | Updated | Nov. 1, 2021   |
| Transcutaneous Electrical Nerve/Joint Stimulators         | Updated | Oct. 1, 2021   |

# **General Information**

The inclusion of a health service (e.g., test, drug, device or procedure) in this bulletin indicates only that UnitedHealthcare is adopting a new policy and/or updated, revised, replaced or retired an existing policy; it does not imply that UnitedHealthcare provides coverage for the health service. Note that most benefit plan documents exclude from benefit coverage health services identified as investigational or unproven/not medically necessary. Physicians and other health care professionals may not seek or collect payment from a member for services not covered by the applicable benefit plan unless first obtaining the member's written consent, acknowledging that the service is not covered by the benefit plan and that they will be billed directly for the service.

Note: The absence of a policy does not automatically indicate or imply coverage. As always, coverage for a health service must be determined in accordance with the member's benefit plan and any applicable federal or state regulatory requirements. Additionally, UnitedHealthcare reserves the right to review the clinical evidence supporting the safety and effectiveness of a medical technology prior to rendering a coverage determination.

UnitedHealthcare respects the expertise of the physicians, health care professionals, and their staff who participate in our network. Our goal is to support you and your patients in making the most informed decisions regarding the choice of quality and cost-effective care, and to support practice staff with a simple and predictable administrative experience. The Medical Policy Update Bulletin was developed to share important information regarding UnitedHealthcare Medical Policy, Medical Benefit Drug Policy, Coverage Determination Guideline, and Utilization Review Guideline updates. When information in this bulletin conflicts with applicable state and/or federal law, UnitedHealthcare follows such applicable federal and/or state law.

## Policy Update Classifications

#### New

New clinical coverage criteria have been adopted for a health service (e.g., test, drug, device or procedure)

### **Updated**

An existing policy has been reviewed and changes have not been made to the clinical coverage criteria; however, items such as the clinical evidence, FDA information, and/or list(s) of applicable codes may have been updated

#### Revised

An existing policy has been reviewed and revisions have been made to the clinical coverage criteria

#### Replaced

An existing policy has been replaced with a new or different policy

#### Retired

The health service(s) addressed in the policy are no longer being managed or are considered to be proven/medically necessary and are therefore not excluded as unproven/not medically necessary services, unless coverage guidelines or criteria are otherwise documented in another policy



The complete library of UnitedHealthcare Medical Policies, Medical Benefit Drug Policies, Coverage Determination Guidelines, and Utilization Review Guidelines is available at UHCprovider.com > Policies and Protocols > Commercial Policies > Medical & Drug Policies and Coverage Determination Guidelines.